Serine racemase inhibitor
AssigneeNational University Corporation University of Toyama
InventorsHisashi Mori, Naoki Toyooka, Mineyuki Mizuguchi, Takayuki Obita, Syuichi Hirono, Hiroaki Goda
Life of this patent
Estimating the term…
Abstract
A novel serine racemase inhibitor exhibits sufficient activity and specificity. The serine racemase inhibitor includes one or more compounds selected from compounds respectively represented by the following general formulas [MM_1], [DR_1], [DR′_1], [LW_1], and [ED_1] as an active ingredient.
Claims8
-8. (canceled)
A serine racemase inhibitor comprising an N-[(acyl)hydrazinocarbothioyl]acetamide derivative represented by a general formula [LW—1], a salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient,
- wherein R1w is a substituted or unsubstituted styryl group, a substituted or unsubstituted benzyl group, or a substituted or unsubstituted cyclohexylmethyl group, R2w is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group that includes an oxygen atom or a sulfur atom as a ring atom, and nw is 0, 1, or 2.
An N-[(acyl)hydrazinocarbothioyl]acetamide derivative represented by a general formula [LW—1d], a salt thereof, a hydrate thereof, or a solvate thereof,
- wherein R13w is a halogen atom, R12w, R14w, R15w, and R16w are independently atoms or substituents selected from a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, and a nitro group, and R2bw is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group that includes an oxygen atom or a sulfur atom as a ring atom.
An N-[(acyl)hydrazinocarbothioyl]acetamide derivative represented by a general formula [LW—1e], a salt thereof, a hydrate thereof, or a solvate thereof,
- wherein R2cw is a substituted or unsubstituted heterocyclic group that includes an oxygen atom or a sulfur atom as a ring atom, and (1) R12w, R14w, and R16w are a hydrogen atom, and R13w and R15w are a halogen atom, or (2) R13w, R14w, and R15w are a hydrogen atom, and R12w and R16w are an alkoxy group.
An N-[(acyl)hydrazinocarbothioyl]acetamide derivative represented by a general formula [LW—1g], a salt thereof, a hydrate thereof, or a solvate thereof,
- wherein R1aw is atoms or substituents selected from a halogen atom, an alkyl group, an alkoxy group, a nitro group, and a hydroxyl group that is optionally protected, and (1) R24w is a halogen atom, and R22w, R23w, R25w, and R26w are a hydrogen atom, or (2) R23w is an alkyl group, and R22w, R24w, R25w, and R26w are a hydrogen atom, or (3) R22w and R26w are a halogen atom, and R23w, R24w, and R25w are a hydrogen atom, or (4) R23W and R25w are a halogen atom, and R22w, R24w, and R26w are a hydrogen atom.
An N-[(acyl)hydrazinocarbothioyl]acetamide derivative represented by a general formula [LW—1c], a salt thereof, a hydrate thereof, or a solvate thereof,
- wherein R2w is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group that includes an oxygen atom or a sulfur as a ring atom, and nw is 0, 1, or 2.
-17. (canceled)
A pharmaceutical composition for treating neurodegenerative diseases or hyperexcitable brain conditions, comprising an N-[(acyl)hydrazinocarbothioyl]acetamide derivative represented by a general formula [LW—1], a salt thereof, a hydrate thereof or a solvate thereof as an active ingredient,
- wherein R1w is a substituted or unsubstituted styryl group, a substituted or unsubstituted benzyl group, or a substituted or unsubstituted cyclohexylmethyl group, R2w is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group that includes an oxygen atom or a sulfur atom as a ring atom, and nw is 0, 1, or 2;
- together with a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.